Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Preischemic treatment with TRC160334 results in a pronounced induction of HSP70 in kidneys by 6 hours while postischemic treatment with TRC160334 results in a pronounced induction of HSP70 in kidneys by 12 hours as compared with the respective vehicle control
Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL
More important
CH4O3S/c1-19-11-24-5-7-28-20(2)12-26(45-28)9-10-40-17-33-36(51-40)37-38(50-33)39(52-40)35-29(49-37)8-6-25(47-35)13-22(42)14-27-31(16-30(46-24)21(19)3)48-32(34(27)44-4)15-23(43)18-41
InChiKey: SJPGLKXXUIEFLO-UHFFFAOYSA-N
ABR-238901 Catalog No.:M17814-C Preischemic treatment with TRC160334 resultsABR 238901 is an orally active and potent S100A8 A9 blocker and inhibits S100A8 A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll like receptor 4). ABR 238901 has the potential for myocardial infarction (MI) research. Product information CAS Number: 1638200 22 2 Molecular Weight: 394. 63 Formula: C11H9BrClN3O4S Chemical Name: 5 bromo N (5 chloro 4 hydroxypyridin 3 yl) 6 methoxypyridine 3 sulfonamide
US$ 69.00
US$ 36.00
US$ 47.90